Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Endometrial Neoplasms × FP-1039 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Neoplasms 1

Interventions

Paclitaxel 31 Carboplatin 24 pembrolizumab 17 Bevacizumab 15 Letrozole 13 Cisplatin 9 Megestrol Acetate 8 dostarlimab 7 olaparib 6 lenvatinib 6 abemaciclib 6 Metformin 6 durvalumab 5 Radiotherapy 5 Gemcitabine 5 Fluorouracil 5 Everolimus 5 Docetaxel 5 temsirolimus 4 rucaparib 4 niraparib 4 Specimen Handling 4 Oxaliplatin 4 Nivolumab 4 Medroxyprogesterone Acetate 4 Magnetic Resonance Spectroscopy 4 Fulvestrant 4 Doxorubicin 4 ridaforolimus 3 mirvetuximab soravtansine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01244438 2021-12-13

Study of FP-1039 in Subjects With Endometrial Cancers

Five Prime Therapeutics, Inc.

Phase 2 Withdrawn

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡